Dark

Check out our API

FSTX
F-star Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Mar 8, 2023

7.12USD0.000%(0.00)987,072

Pre-market

0.00USD-100.000%(-7.12)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 20, 2022

08:15AM EST F-star Announces Issuance Of US Patent Protecting FS118, A Bispecific Antibody Targeting PD-L1 And LAG-3 Benzinga

08:00AM EST F-star Announces Issuance of U.S. Patent Protecting FS118, a GlobeNewswire Inc

Jan 7, 2022

08:00AM EST F-star Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire Inc

Jan 5, 2022

08:49AM EST F-star Therapeutics Inc. (FSTX) said that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. RTTNews

08:00AM EST F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany GlobeNewswire Inc

Dec 7, 2021

09:14AM EST F-star Therapeutics To Present FS222 Trial-In-Progress Update At ESMO Immuno-Oncology Congress 2021 Dec. 8-11 Benzinga

09:05AM EST F-star Therapeutics to Present FS222 Trial-in-Progress Update GlobeNewswire Inc

Nov 29, 2021

08:00AM EST F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it will host an R&D Day webinar on Monday, December 6, 2021, from 8:00 a.m. to 10:00 a.m. ET. GlobeNewswire Inc

Nov 12, 2021

08:18AM EST Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:00AM EST Dr. Michelle Morrow to present on F-stars Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific GlobeNewswire Inc

Nov 11, 2021

08:30AM EST Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced theappointment of Darlene DeptulaHicks, Chief Financial Officer of F-star Therapeutics, Inc., to its board of directors and chair of the audit committee. GlobeNewswire Inc

Nov 10, 2021

08:21AM EST F-star Therapeutics Q3 EPS $(0.52) Beats $(0.58) Estimate Benzinga

08:00AM EST F-star Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 1, 2021

08:00AM EDT F-star Therapeutics, Inc.(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on November 10, 2021, at 9:00 a.m. EST to review third quarter 2021 financial results and provide a corporate update. GlobeNewswire Inc

Oct 20, 2021

08:04AM EDT F-star Therapeutics Reports License Deal With J&J's Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B Benzinga

08:00AM EDT F-star Therapeutics Announces License Agreement with Janssen to GlobeNewswire Inc

Sep 16, 2021

08:10AM EDT F-star Therapeutics Will Present FS120 Phase 1 Trial-In-Progress Update At European Society Of Medical Onoclogy Benzinga

08:00AM EDT F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress GlobeNewswire Inc

Sep 9, 2021

09:00AM EDT F-star Therapeutics, Inc.(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, announced today that F-star will participate next week at the H. C. Wainwright 23rd Annual Global Investment Conference, taking place virtually September 13-15. GlobeNewswire Inc

Aug 18, 2021

06:39AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

Aug 17, 2021

06:31AM EDT SVB Leerink Maintains Outperform on F-star Therapeutics, Lowers Price Target to $35 Benzinga

Aug 12, 2021

09:24AM EDT F-star Therapeutics Q2 EPS $(0.92) Misses $(0.74) Estimate Benzinga

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

08:00AM EDT F-star Therapeutics, Inc.(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces second quarter 2021 financial results and provides a corporate update. GlobeNewswire Inc

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 10, 2021

08:02AM EDT F-star Therapeutics Reports Granted Composition Of Matter Patent For Its Novel Second-Gen STING Agonist, SB 11285 Benzinga

08:00AM EDT F-star Therapeutics is Granted Composition of Matter Patent for GlobeNewswire Inc

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

08:53AM EDT F-star Therapeutics Announces Collaboration With MSD To Evaluate FS120 In Combination With KEYTRUDA Benzinga

08:00AM EDT F-star Therapeutics Announces Collaboration with MSD to Evaluate GlobeNewswire Inc

Aug 2, 2021

10:10AM EDT F-star Therapeutics to Announce Second Quarter Results and Host GlobeNewswire Inc

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 26, 2021

08:04AM EDT F-star Therapeutics Says Early Data From SB 11285 'Encourage Further Dose Escalation' Benzinga

08:00AM EDT F-star Therapeutics Provides Interim Update on SB 11285 GlobeNewswire Inc

Jul 9, 2021

08:00AM EDT F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the company will participate in two virtual investor conference events next week. GlobeNewswire Inc

Jul 8, 2021

12:02PM EDT UPDATE: SVB On F-Star Outperform Initiation: Firm Believes Co. Underappreciated With Several Internal And External Clinical Catalysts Upcoming; Highlights Lag-3 Positive Phase 2/3 Data Coupled With Promising FS118 Data In Multiple Melanoma Trials Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 Benzinga

09:23AM EDT F-star Therapeutics Stock Jumps On Licensing Pact For STING Inhibitors With AstraZeneca Benzinga

08:02AM EDT F-star Therapeutics Enters Exclusive Licensing Agreement With AstraZeneca For Novel STING Inhibitors; F-Star Eligible For Upfront And Near-Term Payments Of $12M And Milestones Of Over $300M Benzinga

07:02AM EDT SVB Leerink Initiates Coverage On F-star Therapeutics with Outperform Rating, Announces Price Target of $39 Benzinga

Jun 9, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2021 Benzinga

06:44AM EDT B. Riley Securities Initiates Coverage On F-star Therapeutics with Buy Rating, Announces Price Target of $28 Benzinga

May 18, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 Benzinga

06:23AM EDT HC Wainwright & Co. Initiates Coverage On F-star Therapeutics with Buy Rating, Announces Price Target of $35 Benzinga

May 17, 2021

02:24PM EDT F-Star Therapeutics shares were trading lower after the company reported Q1 earnings results. Benzinga

08:31AM EDT F-star Therapeutics Q1 Net Loss $9.9 Mln Or $1.08/Shr Vs Loss $7.2 Mln Or $3.92/Shr Last Year RTTNews

08:11AM EDT F-star Therapeutics Q1 EPS $(1.08) Beats $(1.16) Estimate, Sales $2.92M Beat $1.20M Estimate Benzinga

08:00AM EDT F-star Therapeutics, Inc.(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces first quarter 2021 financial results and provides a corporate update. GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 10, 2021

08:00AM EDT F-star Therapeutics to Announce First Quarter Results and GlobeNewswire Inc

May 7, 2021

03:03PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop Benzinga

07:16AM EDT F-star Therapeutics Reports Pricing Of Public Offering Of 9.29 Mln Shares At $7/Shr RTTNews

07:11AM EDT F-star Therapeutics Prices 9.29M Share Common Stock Offering At $7/Share Benzinga

07:00AM EDT F-star Therapeutics, Inc. Announces Pricing of $65 Million Public GlobeNewswire Inc

May 6, 2021

05:45PM EDT F-star Therapeutics Reports Offering Of Common Stock, No Size Disclosed Benzinga

Apr 19, 2021

09:27AM EDT SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model GlobeNewswire Inc

Apr 16, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 Benzinga

06:37AM EDT Oppenheimer Initiates Coverage On F-star Therapeutics with Outperform Rating, Announces Price Target of $30 Benzinga

Apr 10, 2021

09:22AM EDT F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster GlobeNewswire Inc

Apr 8, 2021

10:52AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021 Benzinga

07:04AM EDT William Blair Initiates Coverage On F-star Therapeutics with Outperform Rating Benzinga

Apr 1, 2021

08:04AM EDT F-star Therapeutics Announces Ares Trading S.A. Has Exercised Its Option To Develop An Additional Bispecific Program Under The Ongoing Collaboration With F-Star Benzinga

08:00AM EDT F-star Therapeutics Announces Third Option Exercised by Merck GlobeNewswire Inc

Mar 29, 2021

08:08AM EDT F-Star Therapeutics Reports FY20 Sales $11.26M Down From $28.32M YoY Benzinga

08:00AM EDT F-star Therapeutics, Inc.(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces 2020 full-year financial results and provides corporate update. GlobeNewswire Inc

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 24, 2021

11:49AM EDT Laidlaw & Co. Initiates Coverage On F-star Therapeutics with Buy Rating, Announces Price Target of $32 Benzinga

Mar 16, 2021

08:00AM EDT F-star Therapeutics to Host Full-Year 2020 Investor Call and GlobeNewswire Inc

Mar 4, 2021

08:01AM EST F-star Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Mar 1, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga

06:46AM EST HC Wainwright & Co. Initiates Coverage On F-star Therapeutics with Buy Rating, Announces Price Target of $35 Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Jan 20, 2021

08:02AM EST F-star Therapeutics Reports European Patent Office Granted Patent With Claims Protecting Composition Of Matter Of Co.'s FS118 Molecule Throughout Europe Benzinga

08:00AM EST F-star Granted Composition of Matter Patent for FS118, a GlobeNewswire Inc

Jan 6, 2021

08:00AM EST F-star Therapeutics to Participate in Upcoming Conferences GlobeNewswire Inc

Jan 4, 2021

08:09AM EST F-star Therapeutics Announces First Patient Dosed In FS222 Phase 1 Clinical Trial Benzinga

08:00AM EST FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Companys third bispecific to enter clinical trials GlobeNewswire Inc

Dec 3, 2020

08:11AM EST F-star Therapeutics Says First Patient Dosed In First-in-Class FS120 Phase 1 Trial RTTNews

08:02AM EST F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase PR Newswire

Share